142 related articles for article (PubMed ID: 24308755)
21. Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.
Masaki N; Sugiyama M; Shimada N; Tanaka Y; Nakamuta M; Izumi N; Watanabe S; Tsubota A; Komatsu M; Masaki T; Enomoto N; Yoneda M; Murata K; Ito K; Koike K; Mizokami M
J Gastroenterol Hepatol; 2014 Dec; 29(12):1996-2005. PubMed ID: 24910341
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
[TBL] [Abstract][Full Text] [Related]
23. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
Heo NY; Lim YS; Lee W; Oh M; An J; Lee D; Shim JH; Kim KM; Lee HC; Lee YS; Suh DJ
Clin Mol Hepatol; 2014 Jun; 20(2):177-84. PubMed ID: 25032184
[TBL] [Abstract][Full Text] [Related]
24. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.
Darling JM; Aerssens J; Fanning G; McHutchison JG; Goldstein DB; Thompson AJ; Shianna KV; Afdhal NH; Hudson ML; Howell CD; Talloen W; Bollekens J; De Wit M; Scholliers A; Fried MW
Hepatology; 2011 Jan; 53(1):14-22. PubMed ID: 21254158
[TBL] [Abstract][Full Text] [Related]
25. Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients.
Dzekova-Vidimliski P; Nikolov IG; Matevska-Geshkovska N; Mena S; Rostaing L; Dimovski A; Sikole A
Ren Fail; 2015 Aug; 37(7):1180-4. PubMed ID: 26156685
[TBL] [Abstract][Full Text] [Related]
26. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
[TBL] [Abstract][Full Text] [Related]
27. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
28. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
J Viral Hepat; 2013 Jan; 20(1):59-64. PubMed ID: 23231085
[TBL] [Abstract][Full Text] [Related]
29. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
30. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
Ling Q; Chen J; Zhou H; Zhong J; Chen Y; Ye Q; Zhuo Y; Min N; Shang B
Arch Virol; 2015 Apr; 160(4):1105-12. PubMed ID: 25687192
[TBL] [Abstract][Full Text] [Related]
31. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
[TBL] [Abstract][Full Text] [Related]
32. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
[TBL] [Abstract][Full Text] [Related]
34. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
[TBL] [Abstract][Full Text] [Related]
35. Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.
Zhang R; Shao C; Huo N; Li M; Xu X
Gut Liver; 2016 May; 10(3):446-55. PubMed ID: 26470765
[TBL] [Abstract][Full Text] [Related]
36. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
[TBL] [Abstract][Full Text] [Related]
37. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
[TBL] [Abstract][Full Text] [Related]
38. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
[TBL] [Abstract][Full Text] [Related]
39. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
[TBL] [Abstract][Full Text] [Related]
40. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]